RestorGenex is a specialty biopharmaceutical company focused on developing a portfolio of first-in-class therapeutic products to treat diseases across the ophthalmologic, oncologic and dermatologic space. RestorGenex's lead product is a novel PI3K/Akt/mTOR pathway inhibitor which has completed two Phase I clinical trials for age-related macular degeneration and is in pre-clinical development for glioblastoma multiforme. The current pipeline also includes a "soft" anti-androgen compound for the treatment of acne vulgaris. RestorGenex's novel inhibition of the PI3K pathway and unique targeting of the androgen receptor show promise in a number of additional diseases, which the Company is evaluating for the purpose of creating safe and effective treatments and innovative therapies.
| Website | http://www.restorgenex.com |
| Revenue | $5.6 million |
| Employees | View employees |
| Address | 2150 E Lake Cook Rd Ste 750, Buffalo Grove, Illinois 60089, US |
| Phone | +1 847-777-8092 |
| Industry | Biotechnology Research, Manufacturing General, Manufacturing |
| Competitors | AbbVie, Amgen, Smith+Nephew, Integra LifeSciences, 墨尼克医疗用品（上海）有限公司, Organogenesis, Acelity, KCI USA, Actavis plc (now Allergan), MediWound Ltd. +28 more (view full list) |
| SIC | SIC Code 283 Companies, SIC Code 28 Companies |
| NAICS | NAICS Code 325 Companies, NAICS Code 32 Companies, NAICS Code 3254 Companies, NAICS Code 32541 Companies |
Looking for a particular RestorGenex employee's phone or email?
RestorGenex Questions
The RestorGenex annual revenue was $5.6 million in 2026.
RestorGenex is based in Buffalo Grove, Illinois.
The NAICS codes for RestorGenex are [325, 32, 3254, 32541].
The SIC codes for RestorGenex are [283, 28].
Related Companies
